Savient Pharmaceuticals, a US-based a speciality biopharmaceutical company, has named John Johnson chief executive officer; he will also serve as a member of the company's board of directors. He was most recently a senior vice-president at Lilly and president of Lilly Oncology Business Unit. Before that, Mr Johnson was CEO of ImClone Systems.
New CEO appointed at Savient
Savient Pharmaceuticals, a US-based a speciality biopharmaceutical company, has named John Johnson chief executive officer; he will also serve as a member of the company's board of directors. He was most recently a senior vice-president at Lilly and president of Lilly Oncology Business Unit. Before that, Mr Johnson was CEO of ImClone Systems.
More from Business
• By
PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.
• By
PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.
• By
Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.
• By
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
More from Scrip
• By
The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.
• By
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
• By
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.